三拗汤治疗哮喘:系统综述方案
2019/06/13
摘要
背景：哮喘是一种慢性炎症性疾病，其特征是反复发作的气喘和喘息，通常在夜间或清晨加重，严重程度和频率因人而异。三拗汤作为一种中药复方，在治疗呼吸系统疾病方面有着悠久的临床应用历史。然而，对随机对照文献的系统分析和荟萃分析都不能解释三拗汤治疗哮喘的疗效。因此，我们提供了一个方案来评估三拗汤治疗哮喘的有效性和安全性。
方法：从2018年12月开始对科克伦图书馆、Embase、PubMed、科学网、中国国家知识基础设施、中国生物医学文献数据库、中国科学期刊数据库、万方数据库等电子数据库进行中英文检索。主要测量总有效率、呼气峰流量(PEF)、1秒用力呼气量(FEV1)、用力肺活量(FVC)和FEV1/FVC。使用Stata 15进行meta分析。
结果：本研究将从PEF、FEV1、FVC、FEV1/FVC等几个方面为三拗汤治疗哮喘提供最新证据。
结论：本综述的结果将为评估三拗汤是否有效治疗哮喘提供证据。
普洛斯彼罗注册号:普洛斯彼罗CRD42018117923。
Chen G, Chen Y, Chen Z, Gao S, Zhang P, Zhang H, Huang Y, Lin Y, Wei L.
Abstract
BACKGROUND:Asthma is a chronic inflammatory disease characterized by recurrent attacks of breathlessness and wheezing, which often worsen at night or in the early morning and vary from person to person in severity and frequency. Sanao decoction (SAD), as a traditional Chinese medicine compound, has a long history of clinical application in the treatment of respiratory diseases. Whereas neither systematic nor meta-analysis of randomized controlled articles explain the efficacy of SAD in treating asthma. Therefore, we provide a protocol to evaluate the efficacy and safety of SAD for asthma.
METHODS:From the beginning to December 2018, the following electronic databases will be searched for studies in English or Chinese: the Cochrane Library, Embase, PubMed, Web of Science, the Chinese National Knowledge Infrastructure, the Chinese Biomedical Literature Database, the Chinese Scientific Journal Database, and the Wanfang Database. Total effective rate, peak expiratory flow (PEF), forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and FEV1/FVC will be measured as primary outcomes. Meta-analysis will be performed using the Stata 15.
RESULTS:This study will provide the current evidence of asthma treated with SAD from the several points including PEF, FEV1, FVC, and FEV1/FVC.
CONCLUSION:The consequence of this summary will furnish proof to evaluate if SAD is effective in the treatment of asthma.
PROSPERO REGISTRATION NUMBER: PROSPERO CRD42018117923.
背景：哮喘是一种慢性炎症性疾病，其特征是反复发作的气喘和喘息，通常在夜间或清晨加重，严重程度和频率因人而异。三拗汤作为一种中药复方，在治疗呼吸系统疾病方面有着悠久的临床应用历史。然而，对随机对照文献的系统分析和荟萃分析都不能解释三拗汤治疗哮喘的疗效。因此，我们提供了一个方案来评估三拗汤治疗哮喘的有效性和安全性。
方法：从2018年12月开始对科克伦图书馆、Embase、PubMed、科学网、中国国家知识基础设施、中国生物医学文献数据库、中国科学期刊数据库、万方数据库等电子数据库进行中英文检索。主要测量总有效率、呼气峰流量(PEF)、1秒用力呼气量(FEV1)、用力肺活量(FVC)和FEV1/FVC。使用Stata 15进行meta分析。
结果：本研究将从PEF、FEV1、FVC、FEV1/FVC等几个方面为三拗汤治疗哮喘提供最新证据。
结论：本综述的结果将为评估三拗汤是否有效治疗哮喘提供证据。
普洛斯彼罗注册号:普洛斯彼罗CRD42018117923。
（中日友好医院呼吸与危重症医学科 禹汶伯 摘译 林江涛 审校）
（Medicine (Baltimore). 2019 May;98(18):e15313. doi: 10.1097/MD.0000000000015313.）
Sanao decoction for asthma: Protocol of a systematic review.（Medicine (Baltimore). 2019 May;98(18):e15313. doi: 10.1097/MD.0000000000015313.）
Chen G, Chen Y, Chen Z, Gao S, Zhang P, Zhang H, Huang Y, Lin Y, Wei L.
Abstract
BACKGROUND:Asthma is a chronic inflammatory disease characterized by recurrent attacks of breathlessness and wheezing, which often worsen at night or in the early morning and vary from person to person in severity and frequency. Sanao decoction (SAD), as a traditional Chinese medicine compound, has a long history of clinical application in the treatment of respiratory diseases. Whereas neither systematic nor meta-analysis of randomized controlled articles explain the efficacy of SAD in treating asthma. Therefore, we provide a protocol to evaluate the efficacy and safety of SAD for asthma.
METHODS:From the beginning to December 2018, the following electronic databases will be searched for studies in English or Chinese: the Cochrane Library, Embase, PubMed, Web of Science, the Chinese National Knowledge Infrastructure, the Chinese Biomedical Literature Database, the Chinese Scientific Journal Database, and the Wanfang Database. Total effective rate, peak expiratory flow (PEF), forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and FEV1/FVC will be measured as primary outcomes. Meta-analysis will be performed using the Stata 15.
RESULTS:This study will provide the current evidence of asthma treated with SAD from the several points including PEF, FEV1, FVC, and FEV1/FVC.
CONCLUSION:The consequence of this summary will furnish proof to evaluate if SAD is effective in the treatment of asthma.
PROSPERO REGISTRATION NUMBER: PROSPERO CRD42018117923.
上一篇：
包括中叶支气管的支气管热成形术显著改善重症哮喘患者肺功能及生活质量
下一篇：
早期呼吸道病毒感染与儿童哮喘的发展:系统回顾和荟萃分析的方案
